24-hr Intraocular Pressure Control With SIMBRINZA ®

• Status: Completed
• Trial end date: 2017-01-14
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate differences between treatments in mean change from baseline in 24-hr intraocular pressure (IOP) at Week 4.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Brimonidine Tartrate; Brinzolamide

Criteria

Inclusion Criteria:

• Diagnosis of either open-angle glaucoma or ocular hypertension;

• Able to attend all study related visits and be housed overnight at clinical site for the study assessments;

• Willing and able to sign an informed consent form;

• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• Women of childbearing potential who are pregnant, intend to become pregnant during the study, breast-feeding, or not using adequate birth control;

• Diagnosed with any form of glaucoma other than open angle glaucoma or ocular hypertension;

• Ocular surgeries or procedures excluded by the protocol;

• Diseases, illnesses, infections, or ocular abnormalities excluded by the protocol;

• Best-corrected visual acuity score less than 55 ETDRS letters (equivalent to approximately 20/80 Snellen) in either eye;

• Other protocol-specific exclusion criteria may apply.